🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› UK
Clinical trial register · United Kingdom · industry-sponsored

Industry-sponsored studies with a UK investigative site

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2847 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 22 Sep 2026, 03:15 UTC
2847
Studies in scope
industry-sponsored, all four open statuses
1382
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 2004 Manchester 672 Birmingham 470 Glasgow 437 Cambridge 416
Narrow the register
Recruitment status
Phase
Lead sponsor
AstraZeneca195 Merck Sharp & Dohme LLC116 Hoffmann-La Roche105 Novartis Pharmaceuticals97 Janssen Research & Development, LLC93
Site city
London2004 Manchester672 Birmingham470 Glasgow437 Cambridge416
All 426 cities
Target enrolment
to
2847 of 2847 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Active, closed
HF-TRACK: A UK RCT of an Passive Heart Failure Monitoring and Tracking Device
NCT06334822Heart Failure
Heartfelt Technologies
Not applicable
186
Brough, Hull, Croydon, Bury St Edmunds, Horley, Keighley, Cambridge, London
2024-07-11
Recruiting
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
NCT06264180Advanced Melanoma
Replimune, Inc.
Phase 3
400
Liverpool, London, Manchester
2024-07-11
Recruiting
Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)
NCT06277037Long Term Follow-up
Arbutus Biopharma Corporation
Observational
50
Cardiff, London
2024-07-11
Active, closed
Astroscape: A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II
NCT06392009Tuberous Sclerosis Complex, Focal Cortical Dysplasia
GRIN Therapeutics, Inc.
Phase 1/2
30
Bristol
2024-07-10
Recruiting
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
NCT06515613Platinum-resistant Ovarian Cancer, Testicular Cancer, Endometrial Cancer
Context Therapeutics Inc.
Phase 1
156
London
2024-07-10
Recruiting
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
NCT06127407Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Servier Bio-Innovation LLC
Phase 3
136
Edinburgh, London, Manchester, Oxford
2024-07-09
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
NCT06100744Juvenile Psoriatic Arthritis
AbbVie
Phase 3
40
Sheffield, Bristol, Liverpool
2024-07-08
Active, closed
Versius Paediatrics Study
NCT06539442Robotic Surgical Procedures in Pediatric Urology
CMR Surgical Ltd
Not applicable
150
London, Manchester, Southampton
2024-07-08
Active, closed
A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease
NCT06248619Thyroid Eye Disease
Amgen
Phase 3
89
London
2024-07-05
Recruiting
Study of Subretinally Injected AAVB-081 in Patients With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa
NCT06591793Usher Syndrome, Type 1B
AAVantgarde Bio Srl
Phase 1/2
15
London
2024-07-02
Recruiting
A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)
NCT06431594Solid Tumors, Neoplasms
GlaxoSmithKline
Phase 1
675
Cambridge, London
2024-07-02
Recruiting
Study of WAL0921 in Patients With Glomerular Kidney Diseases
NCT06466135Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy
Walden Biosciences
Phase 2
96
Derby, Leicester, London, Manchester, Salford
2024-07-02
Recruiting
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company
Phase 1
420
London, Manchester
2024-07-01
Active, closed
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
NCT06015737Cutaneous Lupus Erythematosus
AstraZeneca
Phase 3
339
Cambridge, Leeds, London, Newcastle upon Tyne
2024-06-29
Active, closed
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
NCT06331312Polymyalgia Rheumatica
Novartis Pharmaceuticals
Phase 3
162
Barnet, Wolverhampton
2024-06-28
Recruiting
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
NCT06392386Generalized Myasthenia Gravis
argenx
Phase 2/3
12
Oxford
2024-06-28
Recruiting
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
NCT06324357Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
Boehringer Ingelheim
Phase 1/2
768
Cardiff, Leeds, London, Manchester, Newcastle upon Tyne, Nottingham, Sutton
2024-06-28
Active, closed
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06468228Hidradenitis Suppurativa
AbbVie
Phase 3
1,400
Truro, Dunfermline, Gloucester, London, Harrogate, Shoreham-by-Sea, Bristol, Newcastle upon Tyne
2024-06-27
Active, closed
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
NCT06118281Cardiovascular Risk, Acute Myocardial Infarction (AMI)
Novo Nordisk A/S
Phase 3
10,000
Truro, Torquay, Bournemouth, Ashford, Blackpool, Harefield, Edinburgh, Glasgow
2024-06-25
Recruiting
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
NCT06463587Generalized Myasthenia Gravis
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 3
264
London, Nottingham, Sheffield
2024-06-25
Active, closed
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)
NCT06496178Head and Neck Squamous Cell Carcinoma
Merus B.V.
Phase 3
621
Cambridge, Cardiff, Glasgow, Liverpool, London, Manchester, Middlesex, Newcastle upon Tyne
2024-06-25
Recruiting
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
NCT06465810Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR
AstraZeneca
Observational
1,850
Birmingham, Glasgow, London
2024-06-25
Recruiting
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
NCT06393374Triple-Negative Breast Cancer
Merck Sharp & Dohme LLC
Phase 3
1,530
Bristol, Truro, London, Edinburgh, Leeds
2024-06-24
Recruiting
Randomized Trial of UI-EWD vs. Conventional Endoscopic Therapy for Nonvariceal Upper Gastrointestinal Bleeding
NCT06188585Acute Gastrointestinal Bleeding
Medtronic - MITG
Not applicable
278
London
2024-06-21
Recruiting
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
NCT07491172Cardiovascular, Metabolic Disease, Dyslipidemias, Lipid Disorder
CRISPR Therapeutics AG
Phase 1
90
Cambridge, London
2024-06-21
Recruiting
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
NCT06455449Polymyositis, Dermatomyositis
AstraZeneca
Phase 3
240
Edinburgh, London, Wolverhampton
2024-06-20
Recruiting
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
NCT06428409Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer
Merck Sharp & Dohme LLC
Phase 1/2
220
London, Coventry
2024-06-20
Active, closed
Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema
NCT05897424Alpha 1-Antitrypsin Deficiency, Emphysema
Sanofi
Phase 2
185
Dundee, Wythenshawe, Exeter, Southampton, Coventry
2024-06-20
Active, closed
ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency
NCT06462547Gene Mutations, Pseudoxanthoma Elasticum, Arterial Calcification, Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency
Inozyme Pharma
Phase 2
22
Milton Keynes
2024-06-19
Recruiting
A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)
NCT06389877Alpha 1-Antitrypsin Deficiency
Beam Therapeutics Inc.
Phase 1/2
106
London, Southampton
2024-06-19
Recruiting
A Trial of Lu AG13909 in Adult Participants With Cushing's Disease
NCT06471829Cushing's Disease
H. Lundbeck A/S
Phase 2
18
Manchester, Birmingham
2024-06-19
Recruiting
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288Heart Failure
Boehringer Ingelheim
Phase 3
6,000
Barnet, Bristol, Exeter, Halifax, High Wycombe, London, Oldham, Sheffield
2024-06-17
Active, closed
Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia
NCT06455059Hypochondroplasia
BioMarin Pharmaceutical
Phase 3
80
London
2024-06-17
Recruiting
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
NCT06504147Peritoneal Carcinomatosis, Ovarian Cancer
Oncoinvent Solutions AS
Phase 2
114
London, Southampton
2024-06-15
Recruiting
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
NCT06303505Ovarian Cancer, Non-small Cell Lung Cancer
Tubulis GmbH
Phase 1/2
250
London
2024-06-12
Recruiting
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
NCT06285643Parkinson Disease
AskBio Inc
Phase 2
127
Bristol, Cardiff
2024-06-11
Recruiting
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
NCT06422143Non-small Cell Lung Cancer, NSCLC
Merck Sharp & Dohme LLC
Phase 3
851
Londonderry, Torquay, London, Nottingham
2024-06-10
Recruiting
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
NCT06311682Atopic Dermatitis
LEO Pharma
Phase 3
195
Lincoln, London, Sheffield, Southampton
2024-06-10
By invitation
Long-term Follow-up of Participants Dosed With an Investigational Gene Editing Therapy for Cardiovascular Disease
NCT06112327Atherosclerotic Cardiovascular Disease, Heterozygous Familial Hypercholesterolemia, Hypercholesterolemia
Verve Therapeutics, Inc.
Observational
116
London
2024-06-09
Active, closed
A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT06425991Multiple Myeloma
Janssen Research & Development, LLC
Phase 1
108
London, Manchester, Norwich, Plymouth
2024-06-07
Active, closed
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT06082167Head and Neck Squamous Cell Carcinoma
Exelixis
Phase 2/3
600
London, Romford, Manchester, Sutton, Torquay
2024-06-07
Recruiting
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
NCT06056297Neutropenia
X4 Pharmaceuticals
Phase 3
176
Cardiff, London
2024-06-06
Recruiting
Prospective Clinical Assessment Study in Children With Hypochondroplasia
NCT06410976Hypochondroplasia
QED Therapeutics, a BridgeBio company
Observational
150
London, Manchester, Sheffield, Glasgow
2024-06-05
Recruiting
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
NCT06112314Advanced Melanoma
Immunocore Ltd
Phase 3
680
Birmingham, Cambridge, Glasgow, Liverpool, London, Manchester, Oxford, Surrey Quays
2024-06-05
Recruiting
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
NCT06430801Crohn's Disease
Merck Sharp & Dohme LLC
Phase 3
1,200
Cambridge, Exeter, Doncaster, Huddersfield, London, Southampton, Oxford, Bristol
2024-06-05
Recruiting
A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS
NCT06372717Acute Myeloid Leukemia Refractory, Myelodysplastic Syndrome Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts, Acute Myeloid Leukemia, in Relapse
Apollo Therapeutics Ltd
Phase 1
100
Cardiff, Glasgow, London
2024-06-04
Recruiting
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
NCT06479135Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis
Kartos Therapeutics, Inc.
Phase 3
600
Birmingham, Boston, Cambridge, Cardiff, Edinburgh, Gloucester, Harrogate, Leicester
2024-06-03
Recruiting
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
NCT06439277Obesity, Weight Gain
Eli Lilly and Company
Phase 3
300
Cambridge, Glagow, Leeds, Leicester, Liverpool, London, Newcastle upon Tyne, Sheffield
2024-06-03
Recruiting
Post-market Prospective Clinical Study of Nagor Perle Mammary Implants
NCT06013514Breast Reconstruction, Breast Reconstruction Following Mastectomy, Breast Revision, Breast Augmentation
GCA (Eurosilicone)
Observational
60
Manchester
2024-06-01
Recruiting
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy
NCT05861986Muscular Atrophy, Spinal
Hoffmann-La Roche
Phase 4
28
London
2024-05-30
Active, closed
ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)
NCT06373731Age Related Macular Degeneration (ARMD)
Stealth BioTherapeutics Inc.
Phase 3
313
Bristol, Leicester, London, Sunderland
2024-05-30
Active, closed
A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
NCT06360354Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
Amgen
Phase 1
120
Birmingham, London
2024-05-29
Active, closed
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
NCT06412666Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy
Cytokinetics
Phase 2/3
65
Liverpool, London
2024-05-29
Recruiting
A Study of Pitolisant in Patients With Prader-Willi Syndrome
NCT06366464Prader-Willi Syndrome
Harmony Biosciences Management, Inc.
Phase 3
134
Cambridge, Hull, Dundee, Edinburgh
2024-05-28
Recruiting
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
NCT06345729Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
600
Milton Keynes, Exeter
2024-05-24
Recruiting
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
NCT06419374Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
89bio, Inc.
Phase 3
762
Aberdeen, Bristol, Leeds, London, Oxford, Plymouth, Port Talbot, Portsmouth
2024-05-24
Recruiting
Evaluation of the Effects of a Nutritional Intervention of Ketogenic Medium-chain Triglycerides and B-vitamins on Cognitive Functioning in Older Adults With Mild Cognitive Impairment (COGNIKET-MCI)
NCT06347315Mild Cognitive Impairment
Société des Produits Nestlé (SPN)
Not applicable
380
Crowborough, Southampton
2024-05-24
Recruiting
First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors
NCT06402201Select Advanced Solid Tumors
CDR-Life AG
Phase 1
42
Sutton
2024-05-24
Recruiting
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
NCT06351631Thrombocythemia, Essential, Primary Myelofibrosis, Myelofibrosis, Post-polycythemia Vera Myelofibrosis
Merck Sharp & Dohme LLC
Phase 3
400
London, Boston
2024-05-23
Active, closed
Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia
NCT06347133Hypertriglyceridemia
Arrowhead Pharmaceuticals
Phase 3
1,456
Plymouth, London
2024-05-21
Active, closed
A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias
NCT06226571Acute Myeloid Leukemias
Syndax Pharmaceuticals
Phase 1
96
London, Sutton
2024-05-21
Recruiting
The Clinical Utility of BioEP in Diagnostic Decision Making in Epilepsy
NCT06097195Epilepsy
Neuronostics Ltd
Not applicable
559
Truro, Wolverhampton
2024-05-21
Recruiting
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
NCT06237452Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection
Vedanta Biosciences, Inc.
Phase 3
852
Exeter, Bournemouth, Bristol, Edinburgh, London, Sheffield, Swansea
2024-05-20
Active, closed
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
54
Sutton, London, Manchester
2024-05-20
Recruiting
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
NCT06353386Prostatic Neoplasms, Castration-Resistant
Merck Sharp & Dohme LLC
Phase 1/2
220
Cambridge, Glasgow, Preston, London, Birmingham
2024-05-20
Active, closed
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06158841Multiple Myeloma
AbbVie
Phase 3
421
Cambridge, Edinburgh, London, Nottingham, Leeds, Manchester
2024-05-19
Active, closed
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy
NCT06393712Cerebral Amyloid Angiopathy
Alnylam Pharmaceuticals
Phase 2
210
Glasgow, London
2024-05-17
Recruiting
Hearing and Structure Preservation Via ECochG
NCT06268340Hearing Loss, Sensorineural, Severe-to-profound Hearing Loss
Advanced Bionics AG
Not applicable
102
Cambridge
2024-05-15
Active, closed
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
NCT06321302Diabetic Retinopathy
Boehringer Ingelheim
Phase 2
190
Colchester, Liverpool, London, Newcastle upon Tyne
2024-05-15
Active, closed
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
NCT06295731Head and Neck Squamous Cell Carcinoma (HNSCC)
Inhibrx Biosciences, Inc
Phase 2/3
410
Chelsea, Northwood, Newcastle upon Tyne, Sutton, Aberdeen, Cambridge, Manchester, Norwich
2024-05-14
Recruiting
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
NCT05419492Dravet Syndrome
Encoded Therapeutics
Phase 1/2
47
Glasgow, London
2024-05-14
Active, closed
Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP
NCT06079359Hypophosphatasia
Alexion Pharmaceuticals, Inc.
Phase 3
30
Birmingham
2024-05-14
Active, closed
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
NCT06309966Focal Epilepsy
Biohaven Therapeutics Ltd.
Phase 2/3
390
Swansea, Glasgow, Salford, Oxford, Cardiff, London, Newcastle upon Tyne
2024-05-13
Active, closed
Long Term Follow-up Study of Type-1 Gaucher Subjects Post FLT201 Dose (GALILEO-2)
NCT06545136Gaucher Disease, Type 1
Spur Therapeutics
Phase 1/2
75
Salford
2024-05-13
Active, closed
A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome
NCT06283212Dravet Syndrome
Encoded Therapeutics
Phase 1/2
5
Glasgow, London, Sheffield
2024-05-09
Active, closed
A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis
NCT06294925Colitis, Ulcerative
Pfizer
Observational
360
Glasgow, Nottingham, Oxford, Edinburgh, Crumpsall, Kent, London, Newport
2024-05-08
Active, closed
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
NCT06407934Dermatitis Atopic
Sanofi
Phase 3
1,541
Portsmouth, Leicester, London, Glasgow
2024-05-08
Recruiting
Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis
NCT06218875AAA - Abdominal Aortic Aneurysm
W.L.Gore & Associates
Observational
2,000
Leicester, Liverpool, London
2024-05-07
Recruiting
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
NCT06238622Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Boehringer Ingelheim
Phase 3
1,700
Aberdeen, Birmingham, Bristol, Edinburgh, Exeter, Lancaster, Leeds, London
2024-05-06
Recruiting
A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)
NCT06138639Duchenne Muscular Dystrophy
Solid Biosciences Inc.
Phase 1/2
60
London
2024-05-06
Active, closed
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
NCT06356311Gastroesophageal Cancer
Merck Sharp & Dohme LLC
Phase 3
450
Cambridge, Dundee, London, Manchester
2024-05-03
Active, closed
A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)
NCT06402838Alzheimer's Disease
Hoffmann-La Roche
Phase 2
256
Chertsey, Edinburgh, London, Manchester, Southampton
2024-05-02
Recruiting
A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease
NCT06164730Heterozygous Familial Hypercholesterolemia, Premature Coronary Heart Disease
Verve Therapeutics, Inc.
Phase 1
85
Birmingham, Cambridge, Edinburgh, London, Manchester, Nottingham
2024-04-30
Active, closed
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Eli Lilly and Company
Phase 3
10,000
Aberdeen, Birmingham, Bromborough, Coventry, Glasgow, Hull, Ipswich, Lancashire
2024-04-30
By invitation
A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE)
NCT06431893Homocystinuria
Travere Therapeutics, Inc.
Phase 3
100
Birmingham, London, Salford
2024-04-30
Recruiting
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
NCT06338995Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Eli Lilly and Company
Phase 3
510
Bristol, Chelsea, Great Yarmouth, London, Newcastle upon Tyne, Stockport
2024-04-29
Active, closed
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
NCT06346067Advanced or Metastatic NRAS-mutant Melanoma
Erasca, Inc.
Phase 3
78
Preston, City of London, Exeter, London, Manchester
2024-04-29
Active, closed
A Study Evaluating APG777 in Atopic Dermatitis
NCT06395948Atopic Dermatitis
Apogee Therapeutics, Inc.
Phase 2
470
Salford, Dudley, London
2024-04-29
Recruiting
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
NCT05485961End Stage Kidney Disease
CSL Behring
Phase 2/3
3,110
Birmingham, Bradford, Coventry, Derby, Dorchester, Liverpool, London, Londonderry
2024-04-27
Active, closed
Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
NCT05972551Osteogenesis Imperfecta
Amgen
Phase 3
111
Glasgow, Manchester, Sheffield
2024-04-22
Recruiting
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
NCT05980806Myelofibrosis, Moderate Thrombocytopenia, Mild Thrombocytopenia
Karyopharm Therapeutics Inc
Phase 2
58
London
2024-04-22
Recruiting
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
NCT06385080Squamous Cell Carcinoma of Head and Neck
Janssen Research & Development, LLC
Phase 1/2
287
Cambridge, Guildford, London, Manchester
2024-04-22
Recruiting
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
NCT06319820Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC
Phase 3
641
Bristol, London, Newcastle upon Tyne, Sheffield, Southampton, Sutton
2024-04-18
Active, closed
A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT06253221Cardiomyopathy, Hypertrophic
Bristol-Myers Squibb
Phase 3
44
Belfast, London
2024-04-17
Active, closed
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
NCT06298552Generalized Myasthenia Gravis, gMG, Myasthenia Gravis, Generalized, Myasthenia Gravis
argenx
Phase 3
119
Glasgow, Leeds
2024-04-16
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
Sanofi
Phase 3
2,500
Exeter, Kent, London, Swansea, Nottingham, Oxford, Cardiff, Bristol
2024-04-16
Recruiting
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
NCT06312176Breast Neoplasms
Merck Sharp & Dohme LLC
Phase 3
1,200
Londonderry, Truro, London, Blackpool, Nottingham
2024-04-14
Recruiting
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
NCT06307652Heart Failure and Impaired Kidney Function
AstraZeneca
Phase 3
3,850
Airdrie, Barnet, Cambridge, Clydebank, Exeter, Harefield, Hastings, High Wycombe
2024-04-12
By invitation
Long-Term Follow-Up (LTFU) of Subjects Treated With NTLA 2002
NCT06262399Hereditary Angioedema
Intellia Therapeutics
Observational
100
Cambridge
2024-04-12
Recruiting
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
NCT06357533Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
675
Cheltenham, Inverness, London, Norwich, Preston, Truro
2024-04-11
Rows per page Showing 1201–1300 of 2847
Previous 11 12 13 14 15 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site. Derived from ClinicalTrials.gov. Retrieved 22 September 2026. https://priyalifescience.com/clinical-trials-uk?page=13

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.